These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 22087535)
1. Comparative study of the affinity and metabolism of type I and type II binding quinoline carboxamide analogues by cytochrome P450 3A4. Dahal UP; Joswig-Jones C; Jones JP J Med Chem; 2012 Jan; 55(1):280-90. PubMed ID: 22087535 [TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues. Peng CC; Cape JL; Rushmore T; Crouch GJ; Jones JP J Med Chem; 2008 Dec; 51(24):8000-11. PubMed ID: 19053752 [TBL] [Abstract][Full Text] [Related]
3. EaMEAD: Activation energy prediction of cytochrome P450 mediated metabolism with effective atomic descriptors. Kim DN; Cho KH; Oh WS; Lee CJ; Lee SK; Jung J; No KT J Chem Inf Model; 2009 Jul; 49(7):1643-54. PubMed ID: 19545128 [TBL] [Abstract][Full Text] [Related]
4. Kinetic isotope effects implicate a single oxidant for cytochrome P450-mediated O-dealkylation, N-oxygenation, and aromatic hydroxylation of 6-methoxyquinoline. Dowers TS; Jones JP Drug Metab Dispos; 2006 Aug; 34(8):1288-90. PubMed ID: 16714370 [TBL] [Abstract][Full Text] [Related]
5. The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4. Peng CC; Pearson JT; Rock DA; Joswig-Jones CA; Jones JP Arch Biochem Biophys; 2010 May; 497(1-2):68-81. PubMed ID: 20346909 [TBL] [Abstract][Full Text] [Related]
7. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. Venhorst J; Onderwater RC; Meerman JH; Commandeur JN; Vermeulen NP Drug Metab Dispos; 2000 Dec; 28(12):1524-32. PubMed ID: 11095593 [TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Bellec G; Dréano Y; Lozach P; Ménez JF; Berthou F Carcinogenesis; 1996 Sep; 17(9):2029-34. PubMed ID: 8824531 [TBL] [Abstract][Full Text] [Related]
9. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Crewe HK; Ellis SW; Lennard MS; Tucker GT Biochem Pharmacol; 1997 Jan; 53(2):171-8. PubMed ID: 9037249 [TBL] [Abstract][Full Text] [Related]
10. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Kobayashi K; Urashima K; Shimada N; Chiba K Biochem Pharmacol; 2002 Mar; 63(5):889-96. PubMed ID: 11911841 [TBL] [Abstract][Full Text] [Related]
11. CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reaction. Zamperini C; Dreassi E; Vignaroli G; Radi M; Dragoni S; Schenone S; Musumeci F; Valoti M; Antiochia R; Botta M Drug Metab Pharmacokinet; 2014; 29(6):433-40. PubMed ID: 24850316 [TBL] [Abstract][Full Text] [Related]
12. New combined model for the prediction of regioselectivity in cytochrome P450/3A4 mediated metabolism. Oh WS; Kim DN; Jung J; Cho KH; No KT J Chem Inf Model; 2008 Mar; 48(3):591-601. PubMed ID: 18290640 [TBL] [Abstract][Full Text] [Related]
13. The kinetic mechanism for cytochrome P450 metabolism of type II binding compounds: evidence supporting direct reduction. Pearson J; Dahal UP; Rock D; Peng CC; Schenk JO; Joswig-Jones C; Jones JP Arch Biochem Biophys; 2011 Jul; 511(1-2):69-79. PubMed ID: 21530484 [TBL] [Abstract][Full Text] [Related]
14. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes. Danie WA; Syrek M; Ryłko Z; Wójcikowski J Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological characterization of novel analogues of the nicotinic acetylcholine receptor agonist (+/-)-UB-165. Sharples CG; Karig G; Simpson GL; Spencer JA; Wright E; Millar NS; Wonnacott S; Gallagher T J Med Chem; 2002 Jul; 45(15):3235-45. PubMed ID: 12109907 [TBL] [Abstract][Full Text] [Related]
16. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug. Lin HL; Zhang H; Medower C; Hollenberg PF; Johnson WW Drug Metab Dispos; 2011 Feb; 39(2):345-50. PubMed ID: 21068193 [TBL] [Abstract][Full Text] [Related]
17. An analysis of the regioselectivity of aromatic hydroxylation and N-oxygenation by cytochrome P450 enzymes. Dowers TS; Rock DA; Rock DA; Perkins BN; Jones JP Drug Metab Dispos; 2004 Mar; 32(3):328-32. PubMed ID: 14977867 [TBL] [Abstract][Full Text] [Related]
18. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Wang RW; Newton DJ; Scheri TD; Lu AY Drug Metab Dispos; 1997 Apr; 25(4):502-7. PubMed ID: 9107550 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18. Minoletti C; Dijols S; Dansette PM; Mansuy D Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023 [TBL] [Abstract][Full Text] [Related]
20. Selection of human cytochrome P450 1A2 mutants with enhanced catalytic activity for heterocyclic amine N-hydroxylation. Kim D; Guengerich FP Biochemistry; 2004 Feb; 43(4):981-8. PubMed ID: 14744142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]